25.12

0.48% -0.12

Apellis Pharmaceuticals Inc (APLS)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt APLS? Forum Prognose

Schlusskurs vom Vortag:

$25.24

Offen:

$25.1

24-Stunden-Volumen:

955.87K

Relative Volume:

0.37

Marktkapitalisierung:

$3.18B

Einnahmen:

$715.22M

Nettoeinkommen (Verlust:

$-250.10M

KGV:

-12.37

EPS:

-2.03

Netto-Cashflow:

$-205.58M

1W Leistung:

-0.16%

1M Leistung:

+17.93%

6M Leistung:

+45.12%

1J Leistung:

-21.28%

1-Tages-Spanne:

$25.02

$25.33

1-Wochen-Bereich:

$24.56

$25.77

52-Wochen-Spanne:

$16.10

$35.57

Apellis Pharmaceuticals Inc Stock (APLS) Company Profile

Firmenname

Apellis Pharmaceuticals Inc

Sektor

Healthcare (1130)

Branche

Biotechnology (631)

Telefon

617-977-5700

Adresse

100 FIFTH AVENUE, WALTHAM, KY

Mitarbeiter

710

Twitter

@ApellisPharma

Nächster Verdiensttermin

2024-12-05

Neueste SEC-Einreichungen

APLS's Discussions on Twitter

Vergleichen Sie APLS mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
APLS Apellis Pharmaceuticals Inc	25.12	3.19B	715.22M	-250.10M	-205.58M	-2.03
VRTX Vertex Pharmaceuticals Inc	453.36	115.12B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	771.87	81.34B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	397.65	52.48B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	840.95	51.59B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	174.04	37.13B	447.02M	-1.18B	-906.14M	-6.1812

Apellis Pharmaceuticals Inc Stock (APLS) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-06	Eingeleitet	Wolfe Research	Peer Perform
2025-10-15	Eingeleitet	Wells Fargo	Overweight
2025-09-26	Herabstufung	Goldman	Neutral → Sell
2025-05-09	Herabstufung	BofA Securities	Buy → Neutral
2025-05-09	Herabstufung	Raymond James	Strong Buy → Outperform
2025-04-29	Eingeleitet	Cantor Fitzgerald	Overweight
2024-12-17	Herabstufung	Goldman	Buy → Neutral
2024-11-21	Eingeleitet	Morgan Stanley	Equal-Weight
2024-10-25	Eingeleitet	RBC Capital Mkts	Sector Perform
2024-10-16	Eingeleitet	Scotiabank	Sector Outperform
2024-10-16	Eingeleitet	William Blair	Outperform
2024-05-31	Eingeleitet	Piper Sandler	Neutral
2024-02-05	Hochstufung	Jefferies	Hold → Buy
2023-12-14	Herabstufung	Wells Fargo	Overweight → Equal Weight
2023-11-09	Eingeleitet	Goldman	Buy
2023-11-02	Eingeleitet	Mizuho	Neutral
2023-10-06	Hochstufung	JP Morgan	Neutral → Overweight
2023-09-15	Hochstufung	Wells Fargo	Equal Weight → Overweight
2023-08-29	Bestätigt	Citigroup	Buy
2023-08-03	Herabstufung	JP Morgan	Overweight → Neutral
2023-08-01	Herabstufung	BofA Securities	Buy → Neutral
2023-01-03	Herabstufung	Wells Fargo	Overweight → Equal Weight
2022-11-10	Herabstufung	Jefferies	Buy → Hold
2022-07-19	Eingeleitet	H.C. Wainwright	Buy
2022-06-17	Fortgesetzt	Stifel	Buy
2022-04-14	Herabstufung	ROTH Capital	Neutral → Sell
2021-12-08	Eingeleitet	Wells Fargo	Overweight
2021-11-29	Herabstufung	ROTH Capital	Buy → Neutral
2021-09-10	Bestätigt	BMO Capital Markets	Outperform
2021-09-10	Bestätigt	Credit Suisse	Neutral
2021-09-10	Bestätigt	Needham	Buy
2021-09-10	Bestätigt	Oppenheimer	Outperform
2021-09-10	Herabstufung	Wedbush	Outperform → Neutral
2021-08-19	Eingeleitet	Jefferies	Buy
2021-08-19	Hochstufung	Wedbush	Neutral → Outperform
2021-05-21	Eingeleitet	UBS	Buy
2021-04-16	Eingeleitet	Goldman	Buy
2020-11-19	Eingeleitet	Needham	Buy
2020-09-01	Eingeleitet	Stifel	Buy
2020-07-20	Eingeleitet	ROTH Capital	Buy
2020-06-17	Eingeleitet	BTIG Research	Neutral
2020-04-01	Eingeleitet	Raymond James	Strong Buy
2020-03-31	Eingeleitet	BMO Capital Markets	Outperform
2020-03-11	Hochstufung	Wedbush	Underperform → Neutral
2020-01-07	Eingeleitet	SVB Leerink	Mkt Perform
2019-12-19	Eingeleitet	BofA/Merrill	Buy
2019-11-22	Eingeleitet	Wedbush	Underperform
2019-11-05	Eingeleitet	Credit Suisse	Neutral
2019-08-01	Bestätigt	Cantor Fitzgerald	Overweight
2019-07-12	Hochstufung	JP Morgan	Neutral → Overweight
2019-03-29	Eingeleitet	Robert W. Baird	Outperform
2019-01-23	Herabstufung	JP Morgan	Overweight → Neutral
2018-07-30	Hochstufung	B. Riley FBR	Neutral → Buy
2018-05-24	Eingeleitet	Cantor Fitzgerald	Overweight
2018-04-12	Herabstufung	B. Riley FBR, Inc.	Buy → Neutral
2018-02-08	Eingeleitet	B. Riley FBR, Inc.	Buy

Alle ansehen

Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten

Dec 31, 2025

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Receives Average Rating of "Hold" from Analysts - MarketBeat

Dec 31, 2025

Dec 30, 2025

Apellis Pharmaceuticals shows rising relative price performance; still shy of key benchmark - MSN

Dec 30, 2025

Simplify Asset Management Inc. Buys New Stake in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Dec 30, 2025

Institution Moves: How buybacks impact Apellis Pharmaceuticals Inc stock valueJuly 2025 Opening Moves & Weekly Stock Breakout Alerts - moha.gov.vn

Dec 30, 2025

Apellis Pharmaceuticals' chief commercial officer sells shares worth $101,103 - MSN

Dec 30, 2025

Dec 29, 2025

Understanding Momentum Shifts in (APLS) - Stock Traders Daily

Dec 29, 2025

Dec 28, 2025

How risky is Apellis Pharmaceuticals Inc. (1JK) stock compared to peersMarket Timing Techniques & Free Get High Impact Recommendations - bollywoodhelpline.com

Dec 28, 2025

Dec 27, 2025

Highland Capital Management LLC Takes Position in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Dec 27, 2025

Apellis Pharmaceuticals Earnings Notes - Trefis

Dec 27, 2025

Dec 23, 2025

How sustainable is Apellis Pharmaceuticals Inc. stock dividend payoutInstitutional Buying Trends & Affordable Investment Portfolio - bollywoodhelpline.com

Dec 23, 2025

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Apellis Pharmaceuticals (APLS) and Argenx Se (ARGX) - The Globe and Mail

Dec 23, 2025

Dec 22, 2025

Mizuho Securities Maintains Apellis Pharmaceuticals(APLS.US) With Hold Rating - 富途牛牛

Dec 22, 2025

Dec 20, 2025

Will Apellis Pharmaceuticals Inc. (1JK) stock outperform foreign stocksEarnings Risk Report & Reliable Volume Spike Trade Alerts - Улправда

Dec 20, 2025

Why Apellis Pharmaceuticals Inc. stock appeals to dividend seekersWeekly Trade Recap & High Conviction Buy Zone Picks - Улправда

Dec 20, 2025

Will Apellis Pharmaceuticals Inc. stock see PE expansion2025 Trading Recap & Reliable Price Breakout Signals - Улправда

Dec 20, 2025

Stifel maintains Apellis Pharmaceuticals (APLS) buy recommendation - MSN

Dec 20, 2025

Dec 19, 2025

APLS (Apellis Pharmaceuticals) EV-to-OCF : 39.23 (As of Dec. 19, 2025) - GuruFocus

Dec 19, 2025

Apellis Pharmaceuticals stock price target lowered to $48 at Stifel By Investing.com - Investing.com Canada

Dec 19, 2025

Stifel Lowers Price Target for Apellis Pharmaceuticals (APLS) to $48 | APLS Stock News - GuruFocus

Dec 19, 2025

Stifel Nicolaus Cuts Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $48.00 - MarketBeat

Dec 19, 2025

Is Apellis Pharmaceuticals Inc. stock near bottom after decline2025 Pullback Review & AI Forecasted Entry and Exit Points - DonanımHaber

Dec 19, 2025

What technical charts say about Apellis Pharmaceuticals Inc. stock2025 Technical Overview & Comprehensive Market Scan Insights - Улправда

Dec 19, 2025

Dec 18, 2025

Insider Selling: Apellis Pharmaceuticals (NASDAQ:APLS) General Counsel Sells 5,000 Shares of Stock - MarketBeat

Dec 18, 2025

Precision Trading with Apellis Pharmaceuticals Inc. (APLS) Risk Zones - Stock Traders Daily

Dec 18, 2025

Officer Watson Sells 5,000 ($122.5K) Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets

Dec 18, 2025

[Form 4] Apellis Pharmaceuticals, Inc. Insider Trading Activity - Stock Titan

Dec 18, 2025

Dec 16, 2025

Investors in Apellis Pharmaceuticals (NASDAQ:APLS) From Five Years Ago Are Still Down 54%, Even After 3.2% Gain This Past Week - 富途牛牛

Dec 16, 2025

Officer Watson Files To Sell 5,000 Of Apellis Pharmaceuticals Inc [APLS] - TradingView — Track All Markets

Dec 16, 2025

Hudson Bay Capital Management LP Has $8.22 Million Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Dec 16, 2025

Dec 15, 2025

Apellis stock rating reiterated at Outperform by William Blair - Investing.com Canada

Dec 15, 2025

Squarepoint Ops LLC Cuts Stock Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Dec 15, 2025

Dec 13, 2025

Braidwell LP Sells 531,300 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Dec 13, 2025

683 Capital Management LLC Buys 77,000 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Dec 13, 2025

Dec 12, 2025

Apellis Pharmaceuticals: A Good Product That Just Misses The Mark (NASDAQ:APLS) - Seeking Alpha

Dec 12, 2025

Natixis Sells 564,361 Shares of Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Dec 12, 2025

Camber Capital Management LP Acquires New Holdings in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Dec 12, 2025

Dec 11, 2025

Bank of Nova Scotia Makes New Investment in Apellis Pharmaceuticals, Inc. $APLS - MarketBeat

Dec 11, 2025

Dec 10, 2025

Apellis Pharmaceuticals Inc Stock Analysis and ForecastRetail Trading Trends & Low Cost Wealth Building - earlytimes.in

Dec 10, 2025

Mizuho Lowers Price Target on Apellis Pharmaceuticals (APLS) Amid Ongoing Eye Disease Therapy Challenges - MSN

Dec 10, 2025